CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
55.65 ^USD	-1.35%		+0.16%	-11.10%

Apr. 18	Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	MT
Apr. 17	Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	MT

CRISPR Therapeutics AG Terminates Tony W. Ho as Executive Vice President, Research and Development

December 20, 2021 at 08:01 am EST

On December 14, 2021, Tony W. Ho was terminated from his position as Executive Vice President, Research and Development of CRISPR Therapeutics AG. Dr. Ho’s termination is without cause and not the result of any disagreement with the Company.

Latest news about CRISPR Therapeutics AG

Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	Apr. 18	MT
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	Apr. 17	MT
Mizuho Adjusts Price Target on CRISPR Therapeutics to $99 From $82, Maintains Buy Rating	Mar. 06	MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $48 From $46, Maintains Underweight Rating	Feb. 26	MT
Wells Fargo Raises Price Target on CRISPR Therapeutics to $70 From $55, Maintains Equal-Weight Rating	Feb. 22	MT
Barclays Raises Price Target on CRISPR Therapeutics to $80 From $61, Maintains Equal-Weight Rating	Feb. 22	MT
Chardan Ups Price Target on CRISPR Therapeutics to $112 From $110, Keeps Buy Rating	Feb. 22	MT
RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept	Feb. 22	MT
Transcript : CRISPR Therapeutics AG Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 10:00 AM	Feb. 21
Needham Adjusts CRISPR Therapeutics' Price Target to $90 From $88, Keeps Buy Rating	Feb. 21	MT
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases	Feb. 21	MT
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q4 Revenue $201.2M	Feb. 21	MT
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q4 EPS $1.10	Feb. 21	MT
CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
Crispr Therapeutics Ag Insider Sold Shares Worth $1,607,177, According to a Recent SEC Filing	Feb. 16	MT
Wolfe Research Starts Coverage on CRISPR Therapeutics With Peer Perform Rating	Feb. 15	MT
CRISPR Therapeutics to Sell About $280 Million of Common Shares	Feb. 13	MT
CRISPR Therapeutics Secures Conditional Marketing Approval in Europe for Casgevy to Treat Sickle Cell Disease, Transfusion-Dependent Beta Thalassemia	Feb. 13	MT
European Commission Grants Crispr Therapeutics Conditional Marketing Permit for Casgevy	Feb. 13	MT
Crispr Therapeutics Announces European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY?	Feb. 13	CI
CRISPR Therapeutics Gets FDA Approval For Casgevy to Treat Transfusion-Dependent Beta Thalassemia	Jan. 16	MT
CRISPR Therapeutics Announces U.S. Food and Drug Administration Approval of CASGEVY? for the Treatment of Transfusion-Dependent Beta Thalassemia	Jan. 16	CI
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder	Jan. 16	RE
Transcript : CRISPR Therapeutics AG Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 02:15 PM	Jan. 09

Chart CRISPR Therapeutics AG

Duration

Period

More charts

Company Profile

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CRISPR Therapeutics AG

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

55.65 USD

Average target price

88.12 USD

Spread / Average Target

+58.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CRISPR THERAPEUTICS AG	-11.10%	4.79B
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research